S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
NASDAQ:CALT

Calliditas Therapeutics AB (publ) Stock Forecast, Price & News

$32.92
+1.34 (+4.24 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.03
Now: $32.92
$33.18
50-Day Range
$30.00
MA: $32.77
$34.74
52-Week Range
$19.00
Now: $32.92
$38.00
Volume6,284 shs
Average Volume17,177 shs
Market Capitalization$789.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

MarketRank

Overall MarketRank

1.15 out of 5 stars

Medical Sector

875th out of 1,922 stocks

Pharmaceutical Preparations Industry

434th out of 769 stocks

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALT
CUSIPN/A
CIKN/A
Phone46-8411-3005
Employees23

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$19.56 million

Profitability

Net Income$-3,450,000.00

Miscellaneous

Market Cap$789.06 million
Next Earnings Date2/12/2021 (Estimated)
OptionableNot Optionable
$32.92
+1.34 (+4.24 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CALT News and Ratings via Email

Sign-up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Frequently Asked Questions

Is Calliditas Therapeutics AB (publ) a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Calliditas Therapeutics AB (publ) stock.
View analyst ratings for Calliditas Therapeutics AB (publ)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Calliditas Therapeutics AB (publ)?

Wall Street analysts have given Calliditas Therapeutics AB (publ) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Calliditas Therapeutics AB (publ) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Calliditas Therapeutics AB (publ)'s next earnings date?

Calliditas Therapeutics AB (publ) is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for Calliditas Therapeutics AB (publ)
.

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.23.
View Calliditas Therapeutics AB (publ)'s earnings history
.

What price target have analysts set for CALT?

4 brokerages have issued 1 year price objectives for Calliditas Therapeutics AB (publ)'s shares. Their forecasts range from $28.00 to $44.00. On average, they anticipate Calliditas Therapeutics AB (publ)'s share price to reach $38.00 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Calliditas Therapeutics AB (publ)
or view Wall Street analyst' top-rated stocks.

Who are some of Calliditas Therapeutics AB (publ)'s key competitors?

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), (EQX) and Forte Biosciences (FBRX).

Who are Calliditas Therapeutics AB (publ)'s key executives?

Calliditas Therapeutics AB (publ)'s management team includes the following people:
  • Ms. Renee Aguiar-Lucander, Chief Exec. Officer (Age 59)
  • Mr. Mikael Bender, Co-Founder
  • Mr. Fredrik Johansson, Chief Financial Officer (Age 44)
  • Ms. Katayoun Welin-Berger, VP Operations (Age 53)
  • Dr. Johan Haggblad, Chief Scientific Officer (Age 63)
  • Mr. Mikael Widell, Head of Communications & IR (Age 63)
  • Mr. Jonathan A. Schur, Group Gen. Counsel
  • Ms. Ann-Kristin Myde, Head of Clinical Devel. & VP of Project Management (Age 66)
  • Mr. Andrew Udell B.Sc., M.B.A., Head of North America, Commercial (Age 51)
  • Dr. Krassimir Mitchev, Head of Medical Affairs (Age 62)

When did Calliditas Therapeutics AB (publ) IPO?

(CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

What is Calliditas Therapeutics AB (publ)'s stock symbol?

Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT."

When did Calliditas Therapeutics AB (publ)'s lock-up period expire?

Calliditas Therapeutics AB (publ)'s lock-up period expired on Wednesday, December 2nd. Calliditas Therapeutics AB (publ) had issued 4,153,385 shares in its public offering on June 5th. The total size of the offering was $80,991,008 based on an initial share price of $19.50. Since the expiration of Calliditas Therapeutics AB (publ)'s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calliditas Therapeutics AB (publ)'s stock price today?

One share of CALT stock can currently be purchased for approximately $32.92.

How big of a company is Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) has a market capitalization of $789.06 million and generates $19.56 million in revenue each year. The company earns $-3,450,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Calliditas Therapeutics AB (publ) employs 23 workers across the globe.

What is Calliditas Therapeutics AB (publ)'s official website?

The official website for Calliditas Therapeutics AB (publ) is www.calliditas.se.

How can I contact Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The company can be reached via phone at 46-8411-3005 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.